18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
Purpose: This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors.M...
| Publicado en: | Breast Cancer Research Vol. 23; no. 1; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
BioMed Central
8/23/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152043330&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 152043330 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14655411 8UYJ jtl: Breast Cancer Research issn: 14655411 maglogo: N pubinfo: dt: 8/23/2021 vid: 23 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 152043330 152043330 NLM34425871 152043330 10.1186/s13058-021-01464-1 NLM34425871 152043330 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. aug: au: Romine, Perrin E. Peterson, Lanell M. Kurland, Brenda F. Byrd, Darrin W. Novakova-Jiresova, Alena Muzi, Mark Specht, Jennifer M. Doot, Robert K. Link, Jeanne M. Krohn, Kenneth A. Kinahan, Paul E. Mankoff, David A. Linden, Hannah M. affil: Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 1144 Eastlake (Mail Stop LG-200), 98109-1023, Seattle, WA, USA sug: subj: Breast Neoplasms Aromatase Inhibitors Therapeutic Use Deoxyribonucleosides Therapeutic Use Breast Neoplasms Drug Therapy Fludeoxyglucose F 18 Therapeutic Use Aged, 80 and Over Neoadjuvant Therapy Adult Female Breast Neoplasms Surgery Breast Neoplasms Metabolism Mastectomy Middle Age Tomography, Emission-Computed Aged Radiopharmaceuticals Therapeutic Use Human Treatment Outcomes Proteins Metabolism Tumor Markers, Biological Metabolism Comparative Studies Multicenter Studies Evaluation Research Validation Studies Short Portable Mental Status Questionnaire Aged, 80 & over Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Female ab: Purpose: This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors.Methods: In two separate studies, women with early stage ER+ breast cancer underwent either paired FDG-PET (n = 22) or FLT-PET (n = 27) scans prior to endocrine therapy and again in the pre-operative setting. Tissue samples for Ki-67 were taken for all patients both prior to treatment and at the time of surgery.Results: FDG maximum standardized uptake value (SUVmax) declined in 19 of 22 lesions (mean 17% (range -45 to 28%)). FLT SUVmax declined in 24 of 27 lesions (mean 26% (range -77 to 7%)). The Ki-67 index declined in both studies, from pre-therapy (mean 23% (range 1 to 73%)) to surgery [mean 8% (range < 1 to 41%)]. Pre- and post-therapy PET measures showed strong rank-order agreement with Ki-67 percentages for both tracers; however, the percent change in FDG or FLT SUVmax did not demonstrate a strong correlation with Ki-67 index change or Ki-67 at time of surgery.Conclusions: A window-of-opportunity approach using PET imaging to assess early response of breast cancer therapy is feasible. FDG and FLT-PET imaging following a short course of neoadjuvant endocrine therapy demonstrated measurable changes in SUVmax in early stage ER+ positive breast cancers. The percentage change in FDG and FLT-PET uptake did not correlate with changes in Ki-67; post-therapy SUVmax for both tracers was significantly associated with post-therapy Ki-67, an established predictor of endocrine therapy response. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|